Benefits and Risks of Early Antiretroviral Treatment Initiation and 6-Months Isoniazid Prophylaxis in HIV-Infected West African Adults : a Randomized Factorial Trial (ANRS 12136 TEMPRANO).

Trial Profile

Benefits and Risks of Early Antiretroviral Treatment Initiation and 6-Months Isoniazid Prophylaxis in HIV-Infected West African Adults : a Randomized Factorial Trial (ANRS 12136 TEMPRANO).

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Isoniazid; Lopinavir/ritonavir
  • Indications HIV-1 infections; HIV-2 infections; Tuberculosis
  • Focus Therapeutic Use
  • Acronyms TEMPRANO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 19 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top